Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

SLXP 140.55 -1.44 (-1.01%)
price chart
Salix Pharmaceuticals, Ltd. Set To Be Acquired By Allergan, Inc.
Allergan, Inc. (NYSE: AGN) is set to acquire Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) in a deal probably worth more than $10 billion, according to Dow Jones Newswires.
Allergan Said to Revive Talks to Acquire Salix  Bloomberg
Valeant Predicts Strong Results While Defending Business Model  Wall Street Journal
Related articles »  
Salix Pharma Scuttles Cosmo Technologies Merger
Salix would have combined with Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals, in an all-stock deal.
Why Salix Pharmaceuticals (SLXP) Stock Is Surging Today  TheStreet.com
Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) to Ring The Nasdaq Stock Market ...  GlobeNewswire (press release)
Related articles »  
Sell Side's Views On Salix-Actavis Potential Merger
Allergan, in a desperate attempt to fend off Valeant's bid, revived acquisition talks with another pharmaceutical company, Salix Pharmaceuticals, Ltd. (SLXP), in September. Allergan believes that acquisition of Salix would make Allergan a complex and ...
Salix: The Field of Potential Buyers is Vast, Analyst Says  Wall Street Journal (blog)
Exclusive: Actavis plans new merger approach for Allergan - sources  Reuters
Related articles »  
Salix's Xifaxan Sales Expected To Go Downhill
Sales of Salix Pharmaceuticals, Ltd.'s (SLXP) drug Xifaxan face the risk of decline due to availability of new all-oral drugs for treatment of the hepatitis C virus (HCV), according to physician survey along with research conducted by Credit Suisse ...
RSI Alert: Salix Pharmaceuticals (SLXP) Now Oversold
In trading on Monday, shares of Salix Pharmaceuticals Ltd (NASD: SLXP) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $135.60 per share.
Related articles »  
Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) received a price target increase from $155 to $185 by Stifel, which maintained a Buy rating.
Salix Pharmaceuticals Price Target Raised to $185.00 (SLXP)  Ticker Report
Stifel Nicolaus Increases Salix Pharmaceuticals Price Target to $185.00 (SLXP)  Watch List News (press release)
Related articles »  
T. Rowe Unwelcoming Of Salix-Allergan Merger
The financial-services firm's statement is in light of Allergan's recent acquisition discussions with Salix Pharmaceuticals, Ltd. (SLXP), in an attempt to ward off Valeant's bid. The California-based drug maker believes the potential acquisition of ...
Salix Said in Talks to Sell to Actavis as Allergan Fades  Bloomberg
Jackson Square Joins Allergan Investors Against Salix Bid  Businessweek
Related articles »  
Pharma Events To Watch Out For This Week
Big players in the pharmaceutical industry are getting ready to present trial data at the upcoming meeting of the American Association for the Study of Liver Disease (AASLD).
FDA approves expanded use of Salix Pharma's constipation drug  Reuters
FDA Approves RELISTOR´┐Ż Subcutaneous Injection for the Treatment of Opioid ...  MarketWatch
Related articles »  
Pharma Stocks in the News: Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP ...
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) said it has received final Food and Drug Administration approval for its Uceris rectal foam product to induce remission in patients with active mild-to-moderate distal ulcerative colitis.
Related articles »  
Salix Receives $100 Million In Patent Infringement Settlement
Salix Pharmaceuticals, Ltd. (SLXP) announced yesterday, that it has received $100 million in patent settlement from the generic drug maker Par Pharmaceutical Companies, Inc. (PRX).